
Sign up to save your podcasts
Or
James Graham, CEO of Recce Pharmaceuticals, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Recce is working to develop a new class of synthetic anti-infectives designed to address the threat of antibiotic-resistant superbugs.
5
77 ratings
James Graham, CEO of Recce Pharmaceuticals, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Recce is working to develop a new class of synthetic anti-infectives designed to address the threat of antibiotic-resistant superbugs.
1,040 Listeners
31 Listeners
274 Listeners
309 Listeners
331 Listeners
394 Listeners
122 Listeners
318 Listeners
198 Listeners
84 Listeners
88 Listeners
428 Listeners
147 Listeners
18 Listeners
84 Listeners